Rifampicin

證據等級: L5

預測適應症: 10 個

Rifampicin: From Antituberculosis Therapy to Conjunctivitis

One-Sentence Summary

Rifampicin is a rifamycin-class antibiotic classically used against tuberculosis and leprosy; the original indication and mechanism-of-action fields are not recorded in this evidence pack (data gaps DG001/DG002). The TxGNN model predicts it may be effective for Conjunctivitis, with a 99.95% prediction score, but currently 0 registered clinical trials and only 20 literature references — mostly older case reports and one small controlled trachoma trial — support this direction.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack — Rifampicin is classically an antituberculosis/antileprosy rifamycin antibiotic (pending confirmation via DrugBank/TFDA, see DG002)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.95%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for this evidence pack is not available (DG002). Based on general pharmacological classification, rifampicin is a rifamycin that inhibits bacterial DNA-dependent RNA polymerase, giving it broad antibacterial (and some antichlamydial) activity — this is basic drug-class knowledge, not a finding from this evidence pack.

No original indication is recorded in the pack (taiwan_regulatory.licenses and drug.original_indications are both empty), so a direct comparison between “original” and “predicted” indications cannot be made from the supplied data alone.

The literature associated with the conjunctivitis prediction is largely historical: a 1975 controlled trial of topical rifampicin ointment for endemic trachoma (a chlamydial conjunctival infection) in Tunisia, a 1970 in vitro study of anti-trachoma activity, and several bacterial-etiology/susceptibility surveys of conjunctivitis pathogens. Together these suggest a plausible but dated and narrow rationale — rifampicin’s known activity against Chlamydia trachomatis and some Gram-positive conjunctival pathogens — rather than a strong, modern, disease-specific efficacy signal.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1096630	1975	Controlled trial	American Journal of Ophthalmology	Compared topical 1% tetracycline, 1% rifampicin, and 5% boric acid ointments in Tunisian schoolchildren with active trachoma; treatments given twice daily for 10 weeks with follow-up to 39 weeks
6635446	1983	Review	Reviews of Infectious Diseases	Rifampin is the most active antibiotic by weight against Chlamydia trachomatis; as effective as tetracyclines for topical trachoma treatment, but resistance emerges easily in vitro
5411121	1970	Preclinical	Nature	Early study of anti-trachoma activity of rifampicin and rifamycin SV derivatives
5005929	1971	Case report/commentary	Annals of Ophthalmology	Early ophthalmology commentary on rifampicin (abstract not available)
19941479	2010	Review	Current Medicinal Chemistry	Reviews neglected bacterial diseases including trachoma; notes rifampin/streptomycin combinations used for related conditions
33457332	2020	Observational	Advanced Biomedical Research	Bacterial etiology and antibiotic susceptibility of conjunctivitis isolates in Kashan, Iran
21484175	2011	Observational	Journal of Ophthalmic Inflammation and Infection	Bacteriologic and plasmid analysis of conjunctivitis etiologic agents in Lagos, Nigeria
15228931	2004	Observational/Review	Anales de Pediatría	Reviews prevalent bacterial conjunctivitis pathogens and antibiotic sensitivity patterns
8363150	1993	Observational	Anales Españoles de Pediatría	Retrospective microbiologic study of 50 neonatal conjunctivitis cases; 84% positive bacterial culture
14686993	2003	Case report	Clinical Microbiology and Infection	Primary meningococcal conjunctivitis in a 6-year-old, treated topically then with systemic rifampin after diagnosis; no complications

Denmark Market Information

Currently no marketing authorisation on record for Rifampicin in Denmark (market status: Not marketed; 0 authorisations).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note: TFDA/SmPC warnings and contraindications are flagged in this evidence pack as a Blocking data gap (DG001) — safety screening (S1) cannot currently be completed without this data.

Conclusion and Next Steps

Decision: Hold

Rationale:

No clinical trials specifically evaluate rifampicin for conjunctivitis; supporting literature is limited to a 1970s controlled trachoma trial, older case reports, and general antibiotic-susceptibility surveys rather than direct efficacy evidence for conjunctivitis itself.
A Blocking-severity data gap (DG001 — missing TFDA/SmPC warnings and contraindications) prevents even an initial safety assessment, and Rifampicin currently has no Danish marketing authorisation.

(For context: two other TxGNN-flagged candidates in this evidence pack — “multiple endocrine neoplasia” and “HIV infectious disease” — were independently assessed as low-value signals: the former has no supporting trials/literature at all, the latter reflects TB/HIV co-treatment drug-interaction studies rather than direct anti-HIV activity. Both are recommended Hold and are not pursued further in this report.)

To proceed, the following is needed:

Confirmed original indication and mechanism-of-action data (DG002)
TFDA/SmPC warnings, contraindications, and full DDI profile (DG001, Blocking)
A modern, conjunctivitis-specific clinical study (rather than relying on trachoma-adjacent historical data)
Clarification of route-of-administration compatibility (topical ophthalmic vs. systemic) for this indication
Assessment of a Denmark/EU marketing-authorisation pathway, given current “Not marketed” status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.